Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: HairBall who wrote (82912)	3/28/2002 12:46:08 PM
From: marginmike	Read Replies (1) \| Respond to of 99985

just be happy they did-ng-

To: HairBall who wrote (82912)	3/28/2002 1:01:21 PM
From: OX	Respond to of 99985

Aventis Uncovers Tens of Millions of Smallpox Vaccine Doses in Storage Associated Press WASHINGTON -- Aventis SA's (AVE) U.S. unit has discovered stores of smallpox vaccine in its freezers, potentially bolstering the nation's inventory and ensuring an adequate supply in the event of a bioterrorist attack. The vaccine was produced by the French pharmaceuticals giant at its American headquarters in Swiftwater, Pa., and was discovered after the Sept. 11 attacks, according to a spokeswoman for the company in France. Neither she nor the company's U.S. spokesman, Len Lavenda, would provide details. He added the details would be released at a news conference Friday with Health and Human Services Secretary Tommy Thompson. HHS officials had no comment Thursday. The Washington Post Thursday quoted government sources as saying 70 million to 90 million doses of liquid vaccine had been found by Aventis. The vaccine has been stored in freezers since it was made decades ago, the Post reported, citing unnamed sources. It was unclear why its existence had gone undiscovered for so long, exactly when it was discovered or by whom. With the extra time provided by the discovery, companies will be able to fine-tune some of the new vaccine candidates under development, instead of rushing effective but perhaps less-than-perfect vaccines into production as an emergency stopgap measure. Sources told the Post that Aventis is negotiating with the federal government, with the goal of giving the U.S. access to the supply. U.S. anti-terrorism officials, guessing that terrorists could one day gain access to samples of the smallpox virus, have said the country should be prepared for a biological attack. The vaccine must be given within a few days after exposure to smallpox, posing a logistical nightmare if outbreaks were to occur in several locations simultaneously. Smallpox has historically killed about a third of those it infects.